Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Hematol Oncol Clin North Am. 2013 Oct;27(5):905–920. doi: 10.1016/j.hoc.2013.07.007

Table 1.

GIST Targets of currently approved and investigational TKI’s.

KIT PDGFR α,β VEGFR 1,2,3 RET FGFR 1,3
Imatinib + +
Sunitinib + + +
Regorafenib + + + + +
Nilotinib + +
Sorafenib + + +
Masitinib + +
Vatalanib + + +
Dovitinib + + + +
Papzopanib + + + +
Cedarinib +
Crenolanib +